Observational studyBlood advances2026
AI-derived whole-body MRI metrics in patients with multiple myeloma reveal unique insights into body composition and outcomes.
Observational study in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02403102 (Imageguided Theranostics in Multiple Myeloma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Imageguided Theranostics in Multiple Myeloma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractPatients with multiple myeloma are frequently exposed to prolonged, multiline and multidrug treatments, factors that may substantially influence overall health, physical reserve, and physiological resilience. Imaging of organs that are captured by whole-body scans can be opportunistically interrogated to derive direct, quantitative measures of body composition. Advances and standardization of whole-body magnetic resonance imaging (WBMRI) together with recent improvements in artificial intelligence (AI) methodologies for automated organ and tissue segmentation presents an opportunity to complement accurate disease assessments with body composition metrics. We report, to our knowledge, for the first time, development of an AI-based pipeline to enable automated quantitative image-derived phenotypes in nondiseased tissue from WBMRI in patients with multiple myeloma. We have demonstrated that a deep-learning pipeline can derive body composition metrics from routinely acquired clinical WBMRI. Throughout treatment, significant longitudinal changes were observed (P< .001), characterized by a decrease in abdominal skeletal muscle (ASM) alongside transient increases in abdominal subcutaneous and visceral adipose tissue. We have also shown that greater reserves of ASM (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.40-0.89) and abdominal subcutaneous adipose tissue (HR, 0.67; 95% CI, 0.46-0.98) at baseline are associated with better progression-free survival. Conversely increases in visceral adipose tissue over time was associated with inferior progression-free survival (HR, 2.89; 95% CI, 1.65-5.09). These findings support opportunistic body composition phenotyping from diagnostic WBMRI as a scalable biomarker for risk stratification (concordance index, 0.725) and mechanistic study. This trial was registered at www.clinicaltrials.gov as NCT02403102.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.